Author’s Note

Author’s Note

Hello, this is Limido.

BackI was an undergraduate student, I briefly learned about poetry. At that time, my professor who was a poet once said after watching a science documentary (most likely NGC):

“Science is truly literary.”

As a science major who also loved literature and philosophy, it resonated with me a lot.

From then on, I wanted to write a science fiction novel—a story that retains the unique qualities of science fiction without disrupting the web novel format; a story that is reasonably professional, although it might fall short compared to real scientific educational books and contain some errors for the sake of literary progression. I wanted to write a story that observed and affirmed the various attributes of humanity amidst the cold and rigid image of science.

I thought I could write this novel well, but it turned out to be much more challenging than I expected. For a while, I felt like I was carrying a load beyond my capabilities. While there’s a sense of relief in finally laying it down, the feelings of regret and sadness are much stronger.

I learned a lot from this story. Following Ryu Young-Joon and Rosaline, I not only learned about the realm of fiction but also gained considerable knowledge in my field of study. It was demanding, but it was a rewarding and enjoyable journey. Because I gained so much from it, it was truly satisfying work, at least for me.

I genuinely hope that the journey with Ryu Young-Joon and Rosaline was enjoyable for the readers as well, and I would like to thank everyone who read along until the end from the bottom of my heart.

Special thanks to Mr. Im Hak-Du, who consulted on everything from the initial concept of this novel and deserves the position of second author if this were a research paper. Additionally, I would like to extend my special gratitude to my mother and girlfriend, who reviewed the manuscript’s technical details from a non-expert’s perspective and helped smooth out the story progression.

Lastly, as befitting a science fiction novel, I’d like to conclude this work by showing due respect to the great giant who provided me with an immense amount of inspiration and an endless supply of knowledge, all completely free of charge.

Thank you so much for supporting “Super Genius DNA.”

References VịSit no(v)3lb/!n(.)com for new novels

1. Verheijde, J. L. Rady, M. Y. & Potts, M. Neuroscience and Brain Death Controversies: The Elephant in the Room. J. Relig. Health 57, 1745–1763 (2018).

2. G?nger, S. & Schindowski, K. Tailoring formulations for intranasal nose-to-brain delivery: A review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. Pharmaceutics 10, (2018).

3. Kumar, A. & Chordia, N. Role of Microbes in Human Health. Appl. Microbiol. Open Access 03, 2–4 (2017).

4. Yeh, E. et al. Self-powered integrated microfluidic point-of-care low-cost enabling ( SIMPLE ) chip. 1–12 (2017).

5. Zmora, N. et al. Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell 174, 1388-1405.e21 (2018).

6. Lau, W. M. et al. CD44v8-10 is a cancer-specific marker for gastric cancer stem cells. Cancer Res. 74, 2630–2641 (2014).

7. Broutier, L. et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat. Protoc. 11, 1724–1743 (2016).

27. Graham, C., Hewitson, R., Pagliuca, A. & Benjamin, R. Cancer immunotherapy with CAR-T cells - Behold the future. Clin. Med. J. R. Coll. Physicians London 18, 324–328 (2018).

28. Sanders, M. E., Merenstein, D. J., Reid, G., Gibson, G. R. & Rastall, R. A. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat. Rev. Gastroenterol. Hepatol. 16, 605–616 (2019).

29. Daly, M. J. A new perspective on radiation resistance based on Deinococcus radiodurans. Nat. Rev. Microbiol. 7, 237–245 (2009).

30. Clifford Lane, H., La Montagne, J. & Fauci, A. S. Bioterrorism: A clear and present danger. Nat. Med. 7, 1271–1273 (2001).

31. Liu, L. & Choi, S. Self-sustainable, high-power-density bio-solar cells for lab-on-a-chip applications. Lab Chip 17, 3817–3825 (2017).

32. Zhu, H. et al. Development of a longevous two-species biophotovoltaics with constrained electron flow. Nat. Commun. 10, (2019).

33. News, I. N. F. Battling Ebola in a war zone in Congo. Econ. (United Kingdom) 414, 0–1 (2018).

34. GenomeAsia 100K Consortium. The GenomeAsia 100K Project enables genetic discoveries across Asia. Nature 576, 106–111 (2019).

35. Prüfer, K. et al. The bonobo genome compared with the chimpanzee and human genomes. Nature 486, 527–531 (2012).

36. Vingerhoets, A. J. J. M., van de Ven, N. & van der Velden, Y. The social impact of emotional tears. Motiv. Emot. 40, 455–463 (2016).

37. McGuigan, A. et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 24, 4846–4861 (2018).

38. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA. Cancer J. Clin. 69, 7–34 (2019).

39. Ribatti, D. The concept of immune surveillance against tumors. The first theories. Oncotarget 8, 7175–7180 (2017).

40. Sabio, E. & Chan, T. A. The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy. Genome Med. 11, 43 (2019).

41. Sama, S., Hadfield, M. J., Lopetegui Lia, N. & Vredenburgh, J. Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab. Cureus 11, 1–6 (2019).

42. Liu, M. & Guo, F. Recent updates on cancer immunotherapy. Precis. Clin. Med. 1, 65–74 (2018).

43. Shanbhag, S. & Ambinder, R. F. Hodgkin lymphoma: A review and update on recent progress. CA. Cancer J. Clin. 68, 116–132 (2018).

44. Nikolajczyk, B. S., Jagannathan-Bogdan, M., Shin, H. & Gyurko, R. State of the union between metabolism and the immune system in type 2 diabetes. Genes Immun. 12, 239–250 (2011).

45. Ji, Z. et al. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. BMC Cancer 19, 1–9 (2019).